Selective Cytopheretic Device (QUELimmune)
- 5 November 2024
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (1) , 144-146
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
Funding Information
- US Food and Drug Administration (FD005092)
- National Center for Advancing Translational Sciences (TR001324)
This publication has 11 references indexed in Scilit:
- Immunomodulatory effects of a cell processing device to ameliorate dysregulated hyperinflammatory disease statesScientific Reports, 2024
- Selective Cytopheretic Device Use in Continuous Kidney Replacement Therapy in Children: A Cohort Study With a Historical ComparatorKidney Medicine, 2024
- Rationale and Design of NEUTRALIZE-AKI: A Multicenter, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney Injury Requiring Continuous Kidney Replacement TherapyNephron, 2023
- Use of the Selective Cytopheretic Device in Critically Ill ChildrenKidney International Reports, 2021
- Regenerative Medicine and Immunomodulatory Therapy: Insights From the Kidney, Heart, Brain, and LungKidney International Reports, 2018
- A Multi-Center, Randomized, Controlled, Pivotal Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device in Patients with Acute Kidney InjuryPLOS ONE, 2015
- The bioartificial kidney: current status and future promisePediatric Nephrology, 2013
- Intensities of Renal Replacement Therapy in Acute Kidney InjuryClinical Journal of the American Society of Nephrology, 2010
- A Selective Cytopheretic Inhibitory Device to Treat the Immunological Dysregulation of Acute and Chronic Renal FailureBlood Purification, 2010
- Efficacy and Safety of Renal Tubule Cell Therapy for Acute Renal FailureJournal of the American Society of Nephrology, 2008